The emergence of modern lipid-lowering drugs (alirocumab, inclisiran, evolocumab) for the treatment of patients with hypercholesterolemia poses the problem of justifying the choice of optimal therapeutic approaches not only from a clinical but also from an organizational and economic point of view. METHODS: For this purpose, an assessment of the features of budget planning was carried out when providing patients with these drugs based on a budget impact analysis. RESULTS: The conducted cost analysis showed that the lowest annual cost of treating one patient is for inclisiran - 320,100 rubles in the first year and 213,400 rubles in subsequent years, the annual cost of both alirocumab and evolocumab was higher and amounted to 380,380 rubles and 352,021 rubles, respectively. Cost savings for inclisiran over two years were 29.87% and 24.22% compared to alirocumab and evolocumab, respectively, and will tend to increase over time due to the reduction in the number of injections in the second and subsequent years. For the funds required to treat 10 patients with alirocumab and evolocumab for two years, 14 and 13 people, respectively, can be treated with inclisiran. Cold chain conditions for transportation and storage are not required for inclisiran, but are required for alirocumab and evolocumab, accounting for a small proportion of the costs of the drugs in question, but may require additional organizational measures and time resources. CONCLUSION: The conducted assessment of the features of budget planning when providing patients with lipid metabolism disorders demonstrated that with comparable clinical efficacy of alirocumab, inclisiran and evolocumab, the choice of inclisiran compared to alternatives is accompanied not only by significant cost savings, but also avoids the risks of violating the conditions of compliance with the “cold chain” during transportation and storage of the drug. The minimum frequency and frequency of administration of inclisiran ensures better patient compliance with therapy compared to alirocumab and evolocumab, which in real clinical practice can contribute to achieving better control over hypercholesterolemia, which in turn is an important indicator of the effectiveness of dispensary monitoring of patients with coronary heart disease, as well as those who have suffered cardiovascular events. This indicator is monitored within the framework of the Federal Project “Fight against Cardiovascular Diseases”, the main goal of which is to reduce cardiovascular mortality in Russia.